The rise of Sildenafil initially drove a boom for major pharmaceutical companies, but recent shifts present a complicated outlook for shareholders. Off-patent versions are eroding profits, and continued patent challenges add more difficulty to the equation. While certain companies may still gain from adjacent services, the general trend suggests… Read More